JP2017526700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526700A5 JP2017526700A5 JP2017513044A JP2017513044A JP2017526700A5 JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5 JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- monoclonal antibody
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 13
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 13
- 229960002756 azacitidine Drugs 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 10
- 229950009791 durvalumab Drugs 0.000 claims description 7
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 9
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006842 hematologic response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047463P | 2014-09-08 | 2014-09-08 | |
| US62/047,463 | 2014-09-08 | ||
| PCT/US2015/048812 WO2016040238A1 (en) | 2014-09-08 | 2015-09-08 | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526700A JP2017526700A (ja) | 2017-09-14 |
| JP2017526700A5 true JP2017526700A5 (https=) | 2018-03-08 |
Family
ID=54150681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513044A Pending JP2017526700A (ja) | 2014-09-08 | 2015-09-08 | 抗ｐｄ１若しくは抗ｐｄｌ１モノクローナル抗体と組み合わせてシチジン類似体の経口製剤を使用する疾患または障害の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160067336A1 (https=) |
| EP (1) | EP3191104A1 (https=) |
| JP (1) | JP2017526700A (https=) |
| KR (1) | KR20170045237A (https=) |
| CN (1) | CN106604745A (https=) |
| AU (1) | AU2015315435A1 (https=) |
| CA (1) | CA2960490A1 (https=) |
| EA (1) | EA201790543A1 (https=) |
| IL (1) | IL250887A0 (https=) |
| MX (1) | MX2017002875A (https=) |
| SG (1) | SG11201701710SA (https=) |
| WO (1) | WO2016040238A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2016196389A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2017161154A2 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia |
| WO2017214575A1 (en) * | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| WO2018007554A1 (en) * | 2016-07-06 | 2018-01-11 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
| KR20190062515A (ko) * | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| EP4606431A3 (en) * | 2017-02-28 | 2025-11-19 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| JP7382232B2 (ja) * | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| CN111278459A (zh) | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| US20220008383A1 (en) * | 2018-11-13 | 2022-01-13 | Amy Yee | Compositions and methods of enhancing immunotherapies |
| WO2020180904A1 (en) * | 2019-03-04 | 2020-09-10 | North Carolina State University | Drug delivery for combination of epigenetic modulation and immune checkpoint blockade |
| JP2022537551A (ja) | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| KR20210097882A (ko) * | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| US20230144385A1 (en) * | 2020-04-07 | 2023-05-11 | Metanoi Therapeutics, Inc. | Ethanolamine formulation for treating epithelial ovarian carcinoma |
| US11938143B2 (en) | 2021-10-19 | 2024-03-26 | Akirabio, Inc. | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| CN121712524A (zh) | 2023-08-18 | 2026-03-20 | 百时美施贵宝公司 | 包含结合bcma和cd3的抗体的组合物以及治疗方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US8492361B2 (en) * | 2009-02-10 | 2013-07-23 | Celgene Corporation | Methods for treating non-small cell lung cancer using 5-azacytidine |
| WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US20140357567A1 (en) * | 2011-11-01 | 2014-12-04 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
| US10966998B2 (en) * | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
-
2015
- 2015-09-08 MX MX2017002875A patent/MX2017002875A/es unknown
- 2015-09-08 EA EA201790543A patent/EA201790543A1/ru unknown
- 2015-09-08 US US14/847,570 patent/US20160067336A1/en not_active Abandoned
- 2015-09-08 SG SG11201701710SA patent/SG11201701710SA/en unknown
- 2015-09-08 CN CN201580048157.4A patent/CN106604745A/zh not_active Withdrawn
- 2015-09-08 EP EP15766985.4A patent/EP3191104A1/en not_active Withdrawn
- 2015-09-08 KR KR1020177006031A patent/KR20170045237A/ko not_active Abandoned
- 2015-09-08 CA CA2960490A patent/CA2960490A1/en not_active Abandoned
- 2015-09-08 JP JP2017513044A patent/JP2017526700A/ja active Pending
- 2015-09-08 AU AU2015315435A patent/AU2015315435A1/en not_active Abandoned
- 2015-09-08 WO PCT/US2015/048812 patent/WO2016040238A1/en not_active Ceased
-
2017
- 2017-03-02 IL IL250887A patent/IL250887A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526700A5 (https=) | ||
| Feagan et al. | Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin | |
| Huang et al. | Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial | |
| Orman et al. | Clinical and histopathologic features of fluoroquinolone-induced liver injury | |
| JP6787792B2 (ja) | がんの処置のための併用治療 | |
| JP2023516936A5 (https=) | ||
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| Landrum et al. | A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: an NRG oncology/gynecologic oncology group study | |
| JP2013520442A5 (https=) | ||
| CN108883132A (zh) | 用于治疗癌症的方法 | |
| JP2019510785A (ja) | 癌を処置する方法 | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| KR20140040728A (ko) | Pi3k 억제제 화합물을 사용한 중피종 치료 방법 | |
| JP2020523384A5 (https=) | ||
| WO2016168730A1 (en) | Combination treatments with seribantumab | |
| JP2023510199A5 (https=) | ||
| Boardman et al. | A phase I evaluation of extended field radiation therapy with concomitant cisplatin chemotherapy followed by paclitaxel and carboplatin chemotherapy in women with cervical carcinoma metastatic to the para-aortic lymph nodes: an NRG oncology/gynecologic oncology group study | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| US20120115833A1 (en) | Method of treating hepatocellular carcinoma | |
| Chaudhary et al. | Combinatorial effect of arsenic and herbal compounds in telomerase-mediated apoptosis induction in liver cancer | |
| JP2020521786A5 (https=) | ||
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP6948080B2 (ja) | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 | |
| Haley et al. | Implementation of BPaL in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease | |
| Khwaja et al. | High responses rates with single agent belantamab mafodotin in relapsed systemic AL amyloidosis |